Literature DB >> 17469181

Small bowel carcinoid (enterochromaffin cell) neoplasia exhibits transforming growth factor-beta1-mediated regulatory abnormalities including up-regulation of C-Myc and MTA1.

Mark Kidd1, Irvin M Modlin, Roswitha Pfragner, Geeta N Eick, Manish C Champaneria, Anthony K Chan, Robert L Camp, Shrikant M Mane.   

Abstract

BACKGROUND: Although it is known that small intestinal carcinoids are derived from enterochromaffin (EC) cells, these cells remain poorly characterized and little is known of the growth regulatory mechanisms of these neuroendocrine cells. Down-regulation or loss of the transforming growth factor-beta1 (TGFbeta1) cytostatic program and activation of TGFbeta-mediated transcriptional networks is associated with uncontrolled growth and metastasis in other neural tumors, glioblastomas. Whether this phenomenon is common to small intestinal carcinoid tumors was investigated.
METHODS: The effects of TGFbeta1 on cultured normal EC cells (isolated by FACS sorting) and the neoplastic EC cell line, KRJ-I, was assessed using the MTT assay. The TGFbetaRII transcript and protein were identified in tumor cells and the effects of TGFbeta1 on SMAD2 phosphorylation and nuclear translocation quantified. The time-dependent response of SMAD4, SMAD7, c-Myc, and P21(WAF1/CIP1) protein expression and c-Myc and p21(WAF1/CIP1) transcript was measured in response to TGFbeta1 and the transcript expression of candidate downstream targets, MTA1 and E-cadherin, were assessed.
RESULTS: TGFbeta1 inhibited normal EC cell proliferation (IC(50) = 17 pM) but stimulated neoplastic EC cell proliferation (EC(50) = 22 pM). In tumor cells, significantly decreased transcript (P < .01) of TGFbetaRII was identified, but no receptor mutations were identified and protein expression was evident. TGFbeta1 (1 ng/mL) resulted in SMAD2 phosphorylation and <7% nuclear expression compared with 93% in normal EC cells. In neoplastic cells, TGFbeta1 (1 ng/mL) caused a decrease in SMAD4 (>16%, P < .05), whereas SMAD7 and c-Myc transcript and protein were respectively increased >21% (P < .05) and approximately 40% (P < .002). TGFbeta1 (1 ng/mL) also decreased p21(WAF1/CIP1) transcript by 60% (P < .001) and protein that was undetectable at 24 hours. Expression of the downstream targets of the c-Myc pathway, MTA1, was increased (20%) and E-cadherin decreased (30%).
CONCLUSIONS: The neoplastic EC cell is characterized by loss of TGFbeta-1-mediated growth inhibition and, similar to glioblastomas, utilizes the TGFbeta system to induce gene responses associated with growth promotion (c-Myc and the ERK pathway), invasion (E-cadherin), and metastasis (MTA1). Copyright 2007 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17469181     DOI: 10.1002/cncr.22725

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  22 in total

Review 1.  The diversity and commonalities of gastroenteropancreatic neuroendocrine tumors.

Authors:  Simon Schimmack; Bernhard Svejda; Benjamin Lawrence; Mark Kidd; Irvin M Modlin
Journal:  Langenbecks Arch Surg       Date:  2011-01-28       Impact factor: 3.445

Review 2.  EGFR/TGFα and TGFβ/CTGF Signaling in Neuroendocrine Neoplasia: Theoretical Therapeutic Targets.

Authors:  M Kidd; S Schimmack; B Lawrence; D Alaimo; I M Modlin
Journal:  Neuroendocrinology       Date:  2012-06-15       Impact factor: 4.914

Review 3.  Flushing Disorders Associated with Gastrointestinal Symptoms: Part 1, Neuroendocrine Tumors, Mast Cell Disorders and Hyperbasophila.

Authors:  Vaibhav Rastogi; Devina Singh; Joseph J Mazza; Dipendra Parajuli; Steven H Yale
Journal:  Clin Med Res       Date:  2018-04-12

Review 4.  Small bowel neuroendocrine tumors: From pathophysiology to clinical approach.

Authors:  Sofia Xavier; Bruno Rosa; José Cotter
Journal:  World J Gastrointest Pathophysiol       Date:  2016-02-15

5.  Serotonin and the 5-HT7 receptor: the link between hepatocytes, IGF-1 and small intestinal neuroendocrine tumors.

Authors:  Bernhard Svejda; Mark Kidd; Andrew Timberlake; Kathy Harry; Alexander Kazberouk; Simon Schimmack; Ben Lawrence; Roswitha Pfragner; Irvin M Modlin
Journal:  Cancer Sci       Date:  2013-05-24       Impact factor: 6.716

6.  The role of mechanical forces and adenosine in the regulation of intestinal enterochromaffin cell serotonin secretion.

Authors:  A Chin; B Svejda; B I Gustafsson; A B Granlund; A K Sandvik; A Timberlake; B Sumpio; R Pfragner; I M Modlin; M Kidd
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-10-28       Impact factor: 4.052

7.  Loss of DPC4/SMAD4 expression in primary gastrointestinal neuroendocrine tumors is associated with cancer-related death after resection.

Authors:  Christina L Roland; Lee F Starker; Y Kang; Deyali Chatterjee; Jeannelyn Estrella; Asif Rashid; Matthew H Katz; Thomas A Aloia; Jeffrey E Lee; Arvind Dasari; James C Yao; Jason B Fleming
Journal:  Surgery       Date:  2016-11-03       Impact factor: 3.982

8.  Increased expression of 14-3-3β promotes tumor progression and predicts extrahepatic metastasis and worse survival in hepatocellular carcinoma.

Authors:  Tzu-An Liu; Yee-Jee Jan; Bor-Sheng Ko; Shyh-Chang Chen; Shu-Man Liang; Ya-Lin Hung; Chiun Hsu; Tang-Long Shen; Yen-Ming Lee; Pei-Feng Chen; John Wang; Song-Kun Shyue; Jun-Yang Liou
Journal:  Am J Pathol       Date:  2011-10-01       Impact factor: 4.307

9.  The genomic landscape of small intestine neuroendocrine tumors.

Authors:  Michaela S Banck; Rahul Kanwar; Amit A Kulkarni; Ganesh K Boora; Franziska Metge; Benjamin R Kipp; Lizhi Zhang; Erik C Thorland; Kay T Minn; Ramesh Tentu; Bruce W Eckloff; Eric D Wieben; Yanhong Wu; Julie M Cunningham; David M Nagorney; Judith A Gilbert; Matthew M Ames; Andreas S Beutler
Journal:  J Clin Invest       Date:  2013-05-15       Impact factor: 14.808

10.  Differential cytotoxicity of novel somatostatin and dopamine chimeric compounds on bronchopulmonary and small intestinal neuroendocrine tumor cell lines.

Authors:  Mark Kidd; Ignat Drozdov; Richard Joseph; Roswitha Pfragner; Michael Culler; Irv Modlin
Journal:  Cancer       Date:  2008-08-15       Impact factor: 6.860

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.